News coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.9265282938143 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- OraSure Technologies (OSUR) Lifted to “Hold” at Zacks Investment Research (americanbankingnews.com)
- AtriCure (ATRC) versus OraSure Technologies (OSUR) Head-To-Head Survey (americanbankingnews.com)
- OraSure Technologies Supports World AIDS Day With Innovative Programs to Enable HIV Testing (finance.yahoo.com)
- OraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell in Honor of World AIDS Day – GlobeNewswire (press release) (globenewswire.com)
Several research firms have recently issued reports on OSUR. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group reissued a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 12th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 19th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. OraSure Technologies presently has an average rating of “Buy” and a consensus target price of $18.21.
OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The business had revenue of $42.30 million during the quarter, compared to the consensus estimate of $40.87 million. During the same period in the prior year, the business posted $0.11 EPS. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. analysts anticipate that OraSure Technologies will post 0.42 EPS for the current year.
In other OraSure Technologies news, CEO Douglas A. Michels sold 22,923 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Mara G. Aspinall acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were acquired at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the acquisition, the director now directly owns 5,000 shares of the company’s stock, valued at $71,150. The disclosure for this purchase can be found here. Company insiders own 6.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2017/12/04/orasure-technologies-osur-receives-coverage-optimism-rating-of-0-08.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.